Agilent Technologies Outlines Growth Drivers Including China, Replacement Cycles, and Lab Automation
During a J.P. Morgan conference discussion, Agilent Technologies executives highlighted continued growth momentum driven by improving end markets, market-share gains, instrument replacement cycles, and operational improvements under the Ignite transformation program. CEO Padraig McDonnell noted that Agilent's revenue has grown from nearly flat two years ago to 10%–11%, with operating margin expanding over 100 basis points despite tariff challenges. China is a key growth area for Agilent, delivering double-digit growth in pharma and food sectors. The company expects China to remain a mid- to high-single-digit long-term growth market due to investments across pharmaceuticals, chemicals, semiconductors, batteries, and environmental testing. Additionally, replacement cycles in liquid chromatography (LC) and gas chromatography (GC) are contributing significantly to Agilent’s performance. Agilent is also investing heavily in automation and AI-enabled instruments as part of its strategy for autonomous laboratories and scientific intelligence. The company's CDMO business grew 30% year-over-year, with new capacity expected to double site revenue over time. Reshoring orders from major pharmaceutical companies could support a $300 million opportunity by 2030.
Topics: AI integration China market growth drivers lab automation replacement cycles